Aspirin nonresponse in patients with arterial causes of ischemic stroke: Considerations in detection and management

Journal of the Neurological Sciences

Volumn 272, Issue 1-2, 2008, Pages 1-7

  Biller, José ^a  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

Antiplatelet; Arterial ischemic stroke; Aspirin; Resistance; Secondary prevention; Variable platelet response

Indexed keywords

ACETYLSALICYLIC ACID;

CEREBROVASCULAR ACCIDENT; CONFIDENCE INTERVAL; DRUG EFFICACY; DRUG WITHDRAWAL; EPISTAXIS; HUMAN; INTESTINAL BLEEDING; PATIENT COMPLIANCE; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE FUNCTION; TREATMENT REFUSAL;

ASPIRIN; HUMANS; ISCHEMIC ATTACK, TRANSIENT; PLATELET AGGREGATION INHIBITORS; RECURRENCE; STROKE;

EID: 48349123233     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2008.04.023     Document Type: Review

References (77)

1. Rosamond W., Flegal K., Friday G., Furie K., Go A., Greenlund K., et al. Heart disease and stroke statistics-2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 115 (2007) e69-e171
2. Petty G.W., Brown Jr. R.D., Whisnant J.P., Sicks J.D., O'Fallon W.M., and Wiebers D.O. Ischemic stroke subtypes: a population-based study of incidence and risk factors. Stroke 30 (1999) 2513-2516
3. Coull A.J., Lovett J.K., and Rothwell P.M. Population based study of early risk of stroke after transient ischaemic attack or minor stroke: implications for public education and organisation of services. BMJ 328 (2004) 326
4. Hardie K., Hankey G.J., Jamrozik K., Broadhurst R.J., and Anderson C. Ten-year risk of first recurrent stroke and disability after first-ever stroke in the Perth Community Stroke Study. Stroke 35 (2004) 731-735
5. Bhatt D.L., Steg P.G., Ohman E.M., Hirsch A.T., Ikeda Y., Mas J.L., et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 295 (2006) 180-189
6. Sacco R.L., Adams R., Albers G., Alberts M.J., Benavente O., Furie K., et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Stroke 37 (2006) 577-617
7. Albers G.W., Amarenco P., Easton J.D., Sacco R.L., and Teal P. Antithrombotic and thrombolytic therapy for ischemic stroke: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (2004) 483S-512S
8. Hacke W., Kaste M., Bogousslavsky J., Brainin M., Chamorro A., Lees K., et al. European stroke initiative recommendations for stroke management-update 2003. Cerebrovasc Dis 16 (2003) 311-337
9. Messmore Jr. H.L., Jeske W.P., Wehrmacher W., Coyne E., Mobarhan S., Cho L., et al. Antiplatelet agents: current drugs and future trends. Hematol Oncol Clin North Am 19 (2005) 87-117 [vi]
10. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324 (2002) 71-86
11. Algra A., and van Gijn J. Cumulative meta-analysis of aspirin efficacy after cerebral ischaemia of arterial origin. J Neurol Neurosurg Psychiatry 66 (1999) 255
12. Maulaz A.B., Bezerra D.C., Michel P., and Bogousslavsky J. Effect of discontinuing aspirin therapy on the risk of brain ischemic stroke. Arch Neurol 62 (2005) 1217-1220
13. Sibon I., and Orgogozo J.M. Antiplatelet drug discontinuation is a risk factor for ischemic stroke. Neurology 62 (2004) 1187-1189
14. Mousa S.A., Forsythe M.S., Bozarth J.M., and Reilly T.M. Effect of single oral dose of aspirin on human platelet functions and plasma plasminogen activator inhibitor-1. Cardiology 83 (1993) 367-373
15. Burger W., Chemnitius J.M., Kneissl G.D., and Rucker G. Low-dose aspirin for secondary cardiovascular prevention-cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation-review and meta-analysis. J Intern Med 257 (2005) 399-414
16. Becker R., Fintel D.J., and Green D. Aspirin: biology and clinical use. Antithrombotic therapy. 4th ed. (2006), Professional Communications, Inc., Caddo 89-114
17. Michelson A.D. Platelet function testing in cardiovascular diseases. Circulation 110 (2004) e489-e493
18. Falluji N., and Steinhubl S.R. Variable response to antiplatelet therapy: what does it mean to clinicians?. Clevel Clin J Med 74 (2007) 49-55
19. Maree A.O., Curtin R.J., Chubb A., Dolan C., Cox D., O'Brien J., et al. Cyclooxygenase-1 haplotype modulates platelet response to aspirin. J Thromb Haemost 3 (2005) 2340-2345
20. Hillarp A., Palmqvist B., Lethagen S., Villoutreix B.O., and Mattiasson I. Mutations within the cyclooxygenase-1 gene in aspirin non-responders with recurrence of stroke. Thromb Res 112 (2003) 275-283
21. Lanni F., Santulli G., Izzo R., Rubattu S., Zanda B., Volpe M., et al. The Pl(A1/A2) polymorphism of glycoprotein IIIa and cerebrovascular events in hypertension: increased risk of ischemic stroke in high-risk patients. J Hypertens 25 (2007) 551-556
22. Papp E., Havasi V., Bene J., Komlosi K., Czopf L., Magyar E., et al. Glycoprotein IIIA gene (PlA) polymorphism and aspirin resistance: is there any correlation?. Ann Pharmacother 39 (2005) 1013-1018
23. Spranger M., Aspey B.S., and Harrison M.J. Sex difference in antithrombotic effect of aspirin. Stroke 20 (1989) 34-37
24. Gum P.A., Kottke-Marchant K., Poggio E.D., Gurm H., Welsh P.A., Brooks L., et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 88 (2001) 230-235
25. Becker D.M., Segal J., Vaidya D., Yanek L.R., Herrera-Galeano J.E., Bray P.F., et al. Sex differences in platelet reactivity and response to low-dose aspirin therapy. JAMA 295 (2006) 1420-1427
26. Watala C., Golanski J., Pluta J., Boncler M., Rozalski M., Luzak B., et al. Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicylic acid (aspirin)-its relation to metabolic control. Thromb Res 113 (2004) 101-113
27. Hansson L., Zanchetti A., Carruthers S.G., Dahlof B., Elmfeldt D., Julius S., et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 351 (1998) 1755-1762
28. Alexandrova M.L., and Bochev P.G. Oxidative stress during the chronic phase after stroke. Free Radic Biol Med 39 (2005) 297-316
29. Cheng G., Shan J., Xu G., Liu P., Zhou Y., Zhu Y., et al. Relationship between endothelial dysfunction, oxidant stress and aspirin resistance in patients with stable coronary heart disease. J Clin Pharm Ther 32 (2007) 287-292
30. Catella-Lawson F., Reilly M.P., Kapoor S.C., Cucchiara A.J., DeMarco S., Tournier B., et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 345 (2001) 1809-1817
31. MacDonald T.M., and Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 361 (2003) 573-574
32. Kurth T., Glynn R.J., Walker A.M., Chan K.A., Buring J.E., Hennekens C.H., et al. Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs. Circulation 108 (2003) 1191-1195
33. Abaci A., Caliskan M., Bayram F., Yilmaz Y., Cetin M., Unal A., et al. A new definition of aspirin non-responsiveness by platelet function analyzer-100 and its predictors. Platelets 17 (2006) 7-13
34. Ikonomidis I., Lekakis J., Vamvakou G., Andreotti F., and Nihoyannopoulos P. Cigarette smoking is associated with increased circulating proinflammatory and procoagulant markers in patients with chronic coronary artery disease: effects of aspirin treatment. Am Heart J 149 (2005) 832-839
35. Wang J.S., Jen C.J., Kung H.C., Lin L.J., Hsiue T.R., and Chen H.I. Different effects of strenuous exercise and moderate exercise on platelet function in men. Circulation 90 (1994) 2877-2885
36. Pamukcu B., Oflaz H., Acar R.D., Umman S., Koylan N., Umman B., et al. The role of exercise on platelet aggregation in patients with stable coronary artery disease: exercise induces aspirin resistant platelet activation. J Thromb Thrombolysis 20 (2005) 17-22
37. Smith Jr. S.C., Allen J., Blair S.N., Bonow R.O., Brass L.M., Fonarow G.C., et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 113 (2006) 2363-2372
38. Harrison P., Segal H., Blasbery K., Furtado C., Silver L., and Rothwell P.M. Screening for aspirin responsiveness after transient ischemic attack and stroke: comparison of 2 point-of-care platelet function tests with optical aggregometry. Stroke 36 (2005) 1001-1005
39. Lordkipanidze M., Pharand C., Schampaert E., Turgeon J., Palisaitis D.A., and Diodati J.G. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J 28 (2007) 1702-1708
40. Chakroun T., Addad F., Abderazek F., Ben-Farhat M., Hamdi S., Gamra H., et al. Screening for aspirin resistance in stable coronary artery patients by three different tests. Thromb Res 121 (2007) 413-418
41. Gurbel P.A., Bliden K.P., DiChiara J., Newcomer J., Weng W., Neerchal N.K., et al. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study. Circulation 115 (2007) 3156-3164
42. Zimmermann N., Wenk A., Kim U., Kienzle P., Weber A.A., Gams E., et al. Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery. Circulation 108 (2003) 542-547
43. Zimmermann N., Kurt M., Wenk A., Winter J., Gams E., and Hohlfeld T. Is cardiopulmonary bypass a reason for aspirin resistance after coronary artery bypass grafting?. Eur J Cardiothorac Surg 27 (2005) 606-610
44. Helgason C.M., Bolin K.M., Hoff J.A., Winkler S.R., Mangat A., Tortorice K.L., et al. Development of aspirin resistance in persons with previous ischemic stroke. Stroke 25 (1994) 2331-2336
45. Andersen K., Hurlen M., Arnesen H., and Seljeflot I. Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease. Thromb Res 108 (2002) 37-42
46. Buchanan M.R., Schwartz L., Bourassa M., Brister S.J., and Peniston C.M. Results of the BRAT study-a pilot study investigating the possible significance of ASA nonresponsiveness on the benefits and risks of ASA on thrombosis in patients undergoing coronary artery bypass surgery. Can J Cardiol 16 (2000) 1385-1390
47. Chen W.H., Cheng X., Lee P.Y., Ng W., Kwok J.Y., Tse H.F., et al. Aspirin resistance and adverse clinical events in patients with coronary artery disease. Am J Med 120 (2007) 631-635
48. Chen W.H., Lee P.Y., Ng W., Tse H.F., and Lau C.P. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol 43 (2004) 1122-1126
49. Eikelboom J.W., Hirsh J., Weitz J.I., Johnston M., Yi Q., and Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 105 (2002) 1650-1655
50. Gum P.A., Kottke-Marchant K., Welsh P.A., White J., and Topol E.J. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 41 (2003) 961-965
51. Marcucci R., Paniccia R., Antonucci E., Gori A.M., Fedi S., Giglioli C., et al. Usefulness of aspirin resistance after percutaneous coronary intervention for acute myocardial infarction in predicting one-year major adverse coronary events. Am J Cardiol 98 (2006) 1156-1159
52. Pamukcu B., Oflaz H., Onur I., Oncul A., Ozcan M., Umman B., et al. Clinical relevance of aspirin resistance in patients with stable coronary artery disease: a prospective follow-up study (PROSPECTAR). Blood Coagul Fibrinolysis 18 (2007) 187-192
53. Hobikoglu G.F., Norgaz T., Aksu H., Ozer O., Erturk M., Destegul E., et al. The effect of acetylsalicylic acid resistance on prognosis of patients who have developed acute coronary syndrome during acetylsalicylic acid therapy. Can J Cardiol 23 (2007) 201-206
54. Mueller M.R., Salat A., Stangl P., Murabito M., Pulaki S., Boehm D., et al. Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thromb Haemost 78 (1997) 1003-1007
55. Grotemeyer K.H., Scharafinski H.W., and Husstedt I.W. Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients. Thromb Res 71 (1993) 397-403
56. Patrignani P. Aspirin insensitive eicosanoid biosynthesis in cardiovascular disease. Thromb Res 110 (2003) 281-286
57. Maugeri N., Evangelista V., Piccardoni P., Dell'Elba G., Celardo A., de Gaetano G., et al. Transcellular metabolism of arachidonic acid: increased platelet thromboxane generation in the presence of activated polymorphonuclear leukocytes. Blood 80 (1992) 447-451
58. Karim S., Habib A., Levy-Toledano S., and Maclouf J. Cyclooxygenase-1 and -2 of endothelial cells utilize exogenous or endogenous arachidonic acid for transcellular production of thromboxane. J Biol Chem 271 (1996) 12042-12048
59. Cotter G., Shemesh E., Zehavi M., Dinur I., Rudnick A., Milo O., et al. Lack of aspirin effect: aspirin resistance or resistance to taking aspirin?. Am Heart J 147 (2004) 293-300
60. Schwartz K.A., Schwartz D.E., Ghosheh K., Reeves M.J., Barber K., and DeFranco A. Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction. Am J Cardiol 95 (2005) 973-975
61. Valles J., Santos M.T., Fuset M.P., Moscardo A., Ruano M., Perez F., et al. Partial inhibition of platelet thromboxane A2 synthesis by aspirin is associated with myonecrosis in patients with ST-segment elevation myocardial infarction. Am J Cardiol 99 (2007) 19-25
62. Fusegawa Y., Goto S., Handa S., Kawada T., and Ando Y. Platelet spontaneous aggregation in platelet-rich plasma is increased in habitual smokers. Thromb Res 93 (1999) 271-278
63. Rival J., Riddle J.M., and Stein P.D. Effects of chronic smoking on platelet function. Thromb Res 45 (1987) 75-85
64. Sawada M., Kishi Y., Numano F., and Isobe M. Smokers lack morning increase in platelet sensitivity to nitric oxide. J Cardiovasc Pharmacol 40 (2002) 571-576
65. Ambrose J.A., and Barua R.S. The pathophysiology of cigarette smoking and cardiovascular disease: an update. J Am Coll Cardiol 43 (2004) 1731-1737
66. Bornstein N.M., Karepov V.G., Aronovich B.D., Gorbulev A.Y., Treves T.A., and Korczyn A.D. Failure of aspirin treatment after stroke. Stroke 25 (1994) 275-277
67. Lee P.Y., Chen W.H., Ng W., Cheng X., Kwok J.Y., Tse H.F., et al. Low-dose aspirin increases aspirin resistance in patients with coronary artery disease. Am J Med 118 (2005) 723-727
68. Helgason C.M., Tortorice K.L., Winkler S.R., Penney D.W., Schuler J.J., McClelland T.J., et al. Aspirin response and failure in cerebral infarction. Stroke 24 (1993) 345-350
69. Moussouttas M., and Papamitsakis N. Combination antiplatelet agents in ischemic cerebrovascular disease. Mt Sinai J Med 72 (2005) 16-22
70. Alberts M.J., Bergman D.L., Molner E., Jovanovic B.D., Ushiwata I., and Teruya J. Antiplatelet effect of aspirin in patients with cerebrovascular disease. Stroke 35 (2004) 175-178
71. Cox D., Maree A.O., Dooley M., Conroy R., Byrne M.F., and Fitzgerald D.J. Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers. Stroke 37 (2006) 2153-2158
72. Dropinski J., Jakiela B., Sanak M., Wegrzyn W., Biernat M., Dziedzina S., et al. The additive antiplatelet action of clopidogrel in patients with coronary artery disease treated with aspirin. Thromb Haemost 98 (2007) 201-209
73. Eikelboom J.W., Hankey G.J., Thom J., Claxton A., Yi Q., Gilmore G., et al. Enhanced antiplatelet effect of clopidogrel in patients whose platelets are least inhibited by aspirin: a randomized crossover trial. J Thromb Haemost 3 (2005) 2649-2655
74. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348 (1996) 1329-1339
75. Gurbel P.A., and Tantry U.S. Aspirin and clopidogrel resistance: consideration and management. J Interv Cardiol 19 (2006) 439-448
76. Lev E.I., Patel R.T., Maresh K.J., Guthikonda S., Granada J., DeLao T., et al. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. J Am Coll Cardiol 47 (2006) 27-33
77. K. Capell, An easy test for aspirin resistance. In: BusinessWeek. August 13 2007:14.